Sökning: id:"swepub:oai:DiVA.org:kth-316131" >
Radiotheranostic Ag...
Radiotheranostic Agents in Hematological Malignancies
-
- Caers, Jo (författare)
- Univ Liege, Lab Hematol, GIGA I3, Liege, Belgium.;CHU Liege, Dept Hematol, Liege, Belgium.
-
- Duray, Elodie (författare)
- Univ Liege, Lab Hematol, GIGA I3, Liege, Belgium.;Univ Liege, Ctr Prot Engn, Inbios, Liege, Belgium.
-
- Vrancken, Louise (författare)
- Univ Liege, Lab Hematol, GIGA I3, Liege, Belgium.;CHU Liege, Dept Hematol, Liege, Belgium.
-
visa fler...
-
- Marcion, Guillaume (författare)
- Univ Liege, Lab Hematol, GIGA I3, Liege, Belgium.
-
- Bocuzzi, Valentina (författare)
- Univ Liege, Lab Hematol, GIGA I3, Liege, Belgium.
-
- De Veirman, Kim (författare)
- Vrije Univ Brussel, Dept Hematol & Immunol, Brussels, Belgium.
-
- Krasniqi, Ahmet (författare)
- Vrije Univ Brussel, Lab In Vivo Cellular & Mol Imaging Lab ICMI, Brussels, Belgium.
-
- Lejeune, Margaux (författare)
- Univ Liege, Lab Hematol, GIGA I3, Liege, Belgium.
-
- Withofs, Nadia (författare)
- CHU Liege, Dept Nucl Med, Liege, Belgium.
-
- Devoogdt, Nick (författare)
- Vrije Univ Brussel, Lab In Vivo Cellular & Mol Imaging Lab ICMI, Brussels, Belgium.
-
- Dumoulin, Mireille (författare)
- Univ Liege, Ctr Prot Engn, Inbios, Liege, Belgium.
-
- Eriksson Karlström, Amelie (författare)
- KTH,Proteinvetenskap
-
- D'Huyvetter, Matthias (författare)
- Vrije Univ Brussel, Lab In Vivo Cellular & Mol Imaging Lab ICMI, Brussels, Belgium.
-
visa färre...
-
Univ Liege, Lab Hematol, GIGA I3, Liege, Belgium;CHU Liege, Dept Hematol, Liege, Belgium. Univ Liege, Lab Hematol, GIGA I3, Liege, Belgium.;Univ Liege, Ctr Prot Engn, Inbios, Liege, Belgium. (creator_code:org_t)
- 2022-07-05
- 2022
- Engelska.
-
Ingår i: Frontiers in Immunology. - : Frontiers Media SA. - 1664-3224. ; 13
- Relaterad länk:
-
https://doi.org/10.3...
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.3...
-
visa färre...
Abstract
Ämnesord
Stäng
- Radioimmunotherapy (RIT) is a cancer treatment that combines radiation therapy with tumor-directed monoclonal antibodies (Abs). Although RIT had been introduced for the treatment of CD20 positive non-Hodgkin lymphoma decades ago, it never found a broad clinical application. In recent years, researchers have developed theranostic agents based on Ab fragments or small Ab mimetics such as peptides, affibodies or single-chain Abs with improved tumor-targeting capacities. Theranostics combine diagnostic and therapeutic capabilities into a single pharmaceutical agent; this dual application can be easily achieved after conjugation to radionuclides. The past decade has seen a trend to increased specificity, fastened pharmacokinetics, and personalized medicine. In this review, we discuss the different strategies introduced for the noninvasive detection and treatment of hematological malignancies by radiopharmaceuticals. We also discuss the future applications of these radiotheranostic agents.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Radiologi och bildbehandling (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Radiology, Nuclear Medicine and Medical Imaging (hsv//eng)
Nyckelord
- lymphoma
- leukemia
- multiple myeloma
- radiotheranostic
- radionuclide
Publikations- och innehållstyp
- ref (ämneskategori)
- for (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Caers, Jo
-
Duray, Elodie
-
Vrancken, Louise
-
Marcion, Guillau ...
-
Bocuzzi, Valenti ...
-
De Veirman, Kim
-
visa fler...
-
Krasniqi, Ahmet
-
Lejeune, Margaux
-
Withofs, Nadia
-
Devoogdt, Nick
-
Dumoulin, Mireil ...
-
Eriksson Karlstr ...
-
D'Huyvetter, Mat ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Radiologi och bi ...
- Artiklar i publikationen
-
Frontiers in Imm ...
- Av lärosätet
-
Kungliga Tekniska Högskolan